Myriam Labopin

Polytech Paris-UPMC, Lutetia Parisorum, Île-de-France, France

Are you Myriam Labopin?

Claim your profile

Publications (230)1630.6 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Limited therapeutic options are available after relapse of acute leukaemia following first reduced intensity conditioning haematopoietic stem cell transplantation (RIC1). A retrospective study on European Society for Blood and Marrow Transplantation (EBMT) registry data was performed on 234 adult patients with acute leukaemia who received a second RIC transplantation (RIC2) from 2000 to 2012 as a salvage treatment for relapse following RIC1. At the time of RIC2, 167 patients (71.4%) had relapsed or refractory disease, 49 (20.9%) were in second CR and 18 (7.7%) in third or higher CR. With a median follow-up of 21 (1.5-79) months after RIC2, 51 patients are still alive. At 2 years, the cumulative incidence of non-relapse mortality (NRM), relapse incidence (RI), leukaemia-free survival (LFS) and overall survival (OS) were 22.4% (95% confidence interval (CI): 17-28.4), 63.9% (56.7-70.1), 14.6% (8.8-18.5) and 20.5% (14.9-26.1), respectively. In patients with acute myelogenous, biphenotypic and undifferentiated leukaemia (representing 89.8% of all patients), duration of remission following RIC1 >225 days, presence of CR at RIC2, patient's Karnofsky performance status >80 at RIC2 and non-myeloablative conditioning were found to be the strongest predictors of patients' favourable outcome.Bone Marrow Transplantation advance online publication, 5 October 2015; doi:10.1038/bmt.2015.221.
    Bone marrow transplantation 10/2015; DOI:10.1038/bmt.2015.221 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Second allogeneic hematopoietic stem cell transplantation (HSCT2) is a frequently used treatment option for relapse of acute leukemia after first allogeneic transplantation. Remission can be induced in selected patients, but data on long-term outcome and finally cure are limited. To estimate the long-term results of HSCT2, we retrospectively analyzed the course of 286 patients receiving myeloablative HSCT2 between 1985 and 2000, with a median follow-up of 11.3 years. Overall survival (OS) and leukemia-free survival (LFS) at 10 years from HSCT2 were 10±2 and 7±2%, respectively. Cumulative 10-year incidence of relapse and non-relapse mortality were 58±3% and 35±3%, respectively. CR at HSCT2, an interval from first transplant to relapse >10 months and TBI as part of the conditioning for HSCT2 favorably influenced LFS and OS. Patients with all three favorable factors had a 10-year OS of 36±10% and LFS of 25±9%, whereas patients showing no favorable factor had all died before year 5. Although retrospective, the long follow-up of this analysis supports the curative potential of alloHSCT2 in selected patients, who might be identified in advance, based on prognostic factors.Bone Marrow Transplantation advance online publication, 21 September 2015; doi:10.1038/bmt.2015.193.
    Bone marrow transplantation 09/2015; DOI:10.1038/bmt.2015.193 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic hematopoietic transplantation is increasingly used in patients aged 55 years or more with AML. The question of whether outcomes can be improved with an allele-level 8/8 HLA-matched unrelated donor (MUD) rather than an older HLA-matched sibling (MSD, more than 55 years) is still unanswered. We thus analyzed outcomes in 714 patients aged 55 years and older with AML in first CR (CR1) who received PBSCs after a reduced-intensity conditioning hematopoietic cell transplant from a MUD (n=310) or a MSD (n=404) in a recent period (2005-2010). The 3-year cumulative incidences (CIs) of non-relapse mortality were 17% and 23% with MSD and MUD, respectively (P=0.17). The 3-year CIs of relapse were 37% and 30%, respectively (P=0.12), resulting in a 3-year CI of leukemia-free survival of 46% and 47%, respectively (P=0.51). The 3-year overall survival was 49% with both MSD and MUD. In conclusion, HLA-identical sibling donors aged 55 years or more should not be excluded because of age for patients aged 55 years and older with AML in CR1.Bone Marrow Transplantation advance online publication, 14 September 2015; doi:10.1038/bmt.2015.180.
    Bone marrow transplantation 09/2015; DOI:10.1038/bmt.2015.180 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background Hemorrhagic cystitis (HC) is a common complication after hematopoietic allogeneic stem cell transplantation (HSCT) associated with intensity of the conditioning regimen, cyclophosphamide (Cy) therapy, and BK polyomavirus (BKPyV) infection.Methods We analyzed 33 consecutive haploidentical (haplo) HSCT recipients transplanted for hematologic diseases. Eleven patients had a previous transplant. Median follow-up was 11 months. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine + mycophenolate mofetil and post-HSCT Cy.ResultsThirty-two of 33 patients achieved neutrophil recovery. Cumulative incidence (CI) of platelet recovery was 65%. CI grade II–IV acute GVHD was 44%. Twenty patients developed HC in a median time of 38 days. CI of HC at day 180 was 62%. BKPyV was positive in blood and urine of 91% of patients at HC onset. HC resolved in 18/20 patients. Factors associated with HC were previous transplant (P = 0.01) and occurrence of cytomegalovirus reactivation before HC (P = 0.05). Grade II–IV acute GVHD was not associated with HC (P = 0.62). CI of day180 viral infections was 73%. Two-year overall survival (O)S was 50%; HC did not impact OS (P = 0.29).Conclusion The incidence of HC after haplo with post-HSCT Cy is high and is associated with morbidity, especially in high-risk patients such as those with a previous transplant history and with impaired immune reconstitution.This article is protected by copyright. All rights reserved.
    Transplant Infectious Disease 09/2015; DOI:10.1111/tid.12455 · 2.06 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Haploidentical hematopoietic stem cell transplants are increasingly used, but it is unknown whether they have a stronger graft-versus-leukemia (GVL) effect. We analyzed 10 679 acute leukemia patients who underwent HSCT from an HLA-matched sibling donor (MSD, n=9815) or a haploidentical donor (⩾ 2 HLA-antigen disparity, n=864) between 2007 and 2012, reported to the European Group for Blood and Marrow Transplantation. In a Cox regression model, acute and chronic graft-versus-host disease (GVHD) were added as time-dependent variables. There was no difference in probability of relapse between recipients of haploidentical and MSD grafts. Factors of importance for relapse after T-cell replete grafts included remission status at HSCT, Karnofsky score ⩽80, acute GVHD of grade II or higher, and chronic GVHD (P<10(-5)). Patients with post-transplant cyclophosphamide (n=194) had similar outcome as other T-cell replete haploidentical transplants (n=369). Non-relapse mortality was significantly higher in the haploidentical group than in MSD patients (P<10(-5)). Leukemia-free survival was superior in the MSD patients receiving T-cell replete (P<10(-5)) or T-cell depleted grafts (P=0.0006). The risk of relapse was the same in acute leukemia patients who received haploidentical donor grafts as in those given MSD transplants, suggesting a similar GVL effect.Leukemia accepted article preview online, 21 August 2015. doi:10.1038/leu.2015.232.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 08/2015; DOI:10.1038/leu.2015.232 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Bone Marrow Transplantation is a high quality, peer-reviewed journal covering all aspects of clinical and basic haemopoietic stem cell transplantation.
    Bone marrow transplantation 08/2015; DOI:10.1038/bmt.2015.182 · 3.57 Impact Factor
  • N-C Gorin · S Giebel · M Labopin · B N Savani · M Mohty · A Nagler
    [Show abstract] [Hide abstract]
    ABSTRACT: The use of autologous stem cell transplantation (ASCT) as consolidation therapy for adult patients with acute leukemia has declined over time. However, multiple randomized studies in the past have reported lower relapse rates after autologous transplantation compared with chemotherapy and lower non-relapse mortality rates compared with allogeneic transplantation. In addition, quality of life of long-term survivors is better after autologous transplantation than after allogeneic transplantation. Further, recent developments may improve outcomes of autograft recipients. These include the use of IV busulfan and the busulfan+melphalan combination, better detection of minimal residual disease (MRD) with molecular biology techniques, the introduction of targeted therapies and post-transplant maintenance therapy. Therefore, ASCT may nowadays be reconsidered for consolidation in the following patients if and when they reach a MRD-negative status: good- and at least intermediate-1 risk acute myelocytic leukemia in first CR, acute promyelocytic leukemia in second CR, Ph-positive acute lymphocytic leukemia. Conversely, patients with MRD-positive status or high-risk leukemia should not be considered for consolidation with ASCT.Bone Marrow Transplantation advance online publication, 17 August 2015; doi:10.1038/bmt.2015.179.
    Bone marrow transplantation 08/2015; DOI:10.1038/bmt.2015.179 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic hematopoietic stem-cell transplantation (HSCT) is potentially curative for acute leukemia (AL), but carries considerable risk. Machine learning algorithms, which are part of the data mining (DM) approach, may serve for transplantation-related mortality risk prediction. This work is a retrospective DM study on a cohort of 28,236 adult HSCT recipients from the AL registry of the European Group for Blood and Marrow Transplantation. The primary objective was prediction of overall mortality (OM) at 100 days after HSCT. Secondary objectives were estimation of nonrelapse mortality, leukemia-free survival, and overall survival at 2 years. Donor, recipient, and procedural characteristics were analyzed. The alternating decision tree machine learning algorithm was applied for model development on 70% of the data set and validated on the remaining data. OM prevalence at day 100 was 13.9% (n = 3,936). Of the 20 variables considered, 10 were selected by the model for OM prediction, and several interactions were discovered. By using a logistic transformation function, the crude score was transformed into individual probabilities for 100-day OM (range, 3% to 68%). The model's discrimination for the primary objective performed better than the European Group for Blood and Marrow Transplantation score (area under the receiver operating characteristics curve, 0.701 v 0.646; P < .001). Calibration was excellent. Scores assigned were also predictive of secondary objectives. The alternating decision tree model provides a robust tool for risk evaluation of patients with AL before HSCT, and is available online (∼bondi/web1.html). It is presented as a continuous probabilistic score for the prediction of day 100 OM, extending prediction to 2 years. The DM method has proved useful for clinical prediction in HSCT. © 2015 by American Society of Clinical Oncology.
    Journal of Clinical Oncology 08/2015; DOI:10.1200/JCO.2014.59.1339 · 18.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia (AML) with 11q23/MLL rearrangement (MLL-r AML) is allocated to the intermediate or high-risk cytogenetic prognostic category depending on the MLL fusion partner. A more favourable outcome has been reported in patients receiving an allogeneic hematopoietic stem-cell transplantation (alloHSCT), but this has not been confirmed in large series. We analyzed the outcome of alloHSCT among adult patients reported to the ALWP between 2000 and 2010. We identified 159 patients with 11q23/MLL rearranged AML allografted in first complete remission (CR1, n=138) or CR2, mostly corresponding to t(9;11), t(11;19), t(6;11), and t(10;11) translocations. Two-year overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and non-relapse mortality (NRM) was 56±4%, 51±4%, 31±3%, and 17±4%, respectively. The outcome differed according to 11q23/MLL rearrangement, being more favourable in patients with t(9;11) and t(11;19) compared to t(10;11) and t(6;11) (2-year OS: 64±6% and 73±10% vs 40±13% and 24±11%, respectively; P<0.0001). Multivariate analysis for OS identified t(6;11), t(10;11), age>40 years and CR2 as unfavourable features, whereas t(6;11), t(10;11), CR2 and the use of RIC regimen affected poorly LFS. This study confirms the potential role of alloHSCT for adult patients with 11q23/MLL rearranged AML in CR1.Leukemia accepted article preview online, 17 June 2015. doi:10.1038/leu.2015.143.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 06/2015; DOI:10.1038/leu.2015.143 · 10.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction We recently reported that about one third of patients with Crohn’s disease experience prolonged regression of ileocolonic disease following haemopoietic stem cell transplantation (HSCT). Here we compare the characteristics of responders and non-responders. Method Patients with impaired quality-of-life from active Crohn’s disease not amenable to surgery despite treatment with at least 3 immunosuppressive agents all underwent stem cell mobilisation before randomisation to immuno-ablation followed by unselected cyclophosphamide-based conditioning and HSCT after one month (Early HRCT) or one-year (Delayed HS CT). Patients in whom all endoscopic evidence of Crohn’s disease disappeared (SES-CD score of zero) were classified as Responders. Supporting histology was available in 17 of them. Results Forty four patients with ileocolonic involvement underwent mobilisation before randomisation to Early or Delayed HSCT. Of 38 patients that could be classified 14 were Responders. Ten had SES-CD of zero after 1 year, (maintained in the second in 3 of 4 with available data) and 4 achieved responder status in year 2. Four of 6 followed to 4 years remain free of Crohn’s disease vs 1 of 15 non-responders. Responders were significantly more likely to have histologically normal segments post HSCT (Table 1) A Responder status tended to be more likely with no family history (39% vs 20%), in non-smokers (54% vs 30%), with early-onset of disease (Montreal A1, 46% vs 32%)) and with more than 10 year history (46% vs 17%); those with pure colonic involvement (L2) were less likely to respond than those with ileal involvement (L1, L3, 14% vs 43%) but these fell short of statistical significance on univariate analysis. Conclusion A group of patients can be identified who have a substantial and long lasting regression of Crohn’s disease following HSCT. Endoscopic response following HSCT is associated with regression of histological evidence of Crohn’s disease. Disclosure of interest None Declared.
    Gut 06/2015; 64(Suppl 1):A96.2-A97. DOI:10.1136/gutjnl-2015-309861.197 · 14.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin D has emerged as a central player in the immune system, with its deficiency being implicated in the pathogenesis of several autoimmune diseases, including chronic GvHD. This is a retrospective cohort analysis of 166 patients, who underwent allogeneic hematopoietic stem cell transplantation (HSCT) at the Karolinska University Hospital, evaluating GvHD, graft failure, infectious complications and survival after HSCT in relation to pre-transplantation vitamin D levels. Most of the patients were deficient in vitamin D before HSCT (median 42 nmol/L). In multivariate analysis, vitamin D level before HSCT was identified as a significant independent risk factor for development of cGvHD. The increased incidence of cGvHD was not coupled to better disease-free survival; instead there was a trend towards lower overall survival in the vitamin D-deficient patients. In addition, we found a significant correlation between vitamin D deficiency and incidence of CMV disease, with no case of CMV disease occurring in patients with sufficient levels of vitamin D before HSCT. Our results support a role of vitamin D in immune tolerance following HSCT. These findings could be highly relevant for the care of HSCT patients, and prospective, randomized studies on the effect of vitamin D supplementation are therefore needed.Bone Marrow Transplantation advance online publication, 1 June 2015; doi:10.1038/bmt.2015.123.
    Bone marrow transplantation 06/2015; 50(9). DOI:10.1038/bmt.2015.123 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate- or poor-risk AML. Relapse incidence was lower with MAC in poor- and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate- and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics.Bone Marrow Transplantation advance online publication, 1 June 2015; doi:10.1038/bmt.2015.121.
    Bone marrow transplantation 06/2015; 50(8). DOI:10.1038/bmt.2015.121 · 3.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Haemopoietic stem cell transplantation (HSCT) leads to complete regression of endoscopic signs of Crohn’s disease in about one third of patients, implying an alteration in the natural history of Crohn’s disease. We investigated whether these substantial changes were also seen histologically. Method Patients with impaired quality-of-life from active Crohn’s disease not amenable to surgery despite treatment with at least 3 immunosuppressive agents all underwent stem cell mobilisation before randomisation to immuno-ablation followed by unselected cyclophosphamide-based conditioning and HSCT after one month (Early HSCT) or one-year (Delayed HSCT). They underwent full ileocolonoscopy at baseline and after one and two years. Endoscopic involvement and activity were assessed using the Simple Endoscopic Score of Crohn’s disease (SES CD) in which a value of zero means no evidence of active or inactive Crohn’s disease in any examined segment of the ileum or colon. In 17 patients segments were biopsied systematically for blinded histological assessment, using ECCO-approved scales for intensity and diffuseness of acute and chronic inflammation, granulomas, ulceration, distortion and metaplasia. Results There was a strong correlation between endoscopic findings and histology (Table 1). The % of colonic biopsy samples that were histologically normal rose from 39% (baseline) to 50% at 1 year and 78% at 2 years after Early HSCT (p = 0.039). In patients undergoing Delayed HSCT values were 52% (baseline), 50% 1 year after mobilisation only and 75% after a further year following delayed HSCT (p = 0.329). Improvements were mainly due to reduction or regression of acute and chronic inflammatory changes. Conclusion Blinded histological assessments fortify the evidence that HSCT can have a profound objective benefit in Crohn’s disease. Disclosure of interest None Declared.
    Gut 06/2015; 64(Suppl 1):A97.1-A97. DOI:10.1136/gutjnl-2015-309861.198 · 14.66 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia with monosomal karyotype (MK AML) carries a very poor prognosis, even after allogeneic stem cell transplantation (SCT). However, SCT remains the only curative option in this high-risk population. Because myeloablative conditioning regimen (MAC) is associated with less relapse, we hypothesized that more intensive conditioning regimen might be beneficial for MK AML patients. We reviewed 303 patients over age 45 diagnosed with either de novo or secondary MK AML, One hundred and five patients received a MAC and 198 a reduced-intensity conditioning (RIC). The median age at SCT was 57 year-old, significantly lower in the MAC (53 year-old) than in the RIC group (59 year-old). The median follow-up was 42 months (range 3-156 months). The 3-year overall survival (OS), leukemia-free survival (LFS) and relapse rate (RR) were not significantly different between both groups with overall values of 34%, 29% and 51%, respectively. On the contrary, the 3-year non-relapse mortality (NRM) was significantly higher in MAC recipients (28%) compared to RIC patients (16%, p=0.004). The incidence of grade II to IV acute graft-versus-host disease (GvHD) was significantly higher after a MAC (30.5%) than after a RIC (19.3%, p=0.02). That of chronic GvHD was comparable between both groups (35%) and did not impact on LFS. Interestingly, within our MK AML cohort, hypodiploidy was significantly associated with worse outcomes. Due to reduced toxicity and comparable OS, LFS and RR, RIC appears as a good transplant option in the very high-risk population, including older patients, diagnosed with MK AML. This article is protected by copyright. All rights reserved. © 2015 Wiley Periodicals, Inc.
    American Journal of Hematology 05/2015; 90(8). DOI:10.1002/ajh.24069 · 3.80 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic hematopoietic cell transplantation is a potentially curative treatment in patients with acute myeloid leukemia. Recent advances in the field of hematopoietic cell allografting have resulted in a practice shift, favoring less intense preparative regimens. We present results of a retrospective comparative analysis of two preparative regimens, namely FB2 (IV fludarabine plus IV busulfan 6.4mg/kg±10%) and FB4 (IV fludarabine plus IV busulfan 12.8mg/kg ±10%), in patients with acute myeloid leukemia undergoing hematopoietic cell allografting in second complete remission at EBMT participating centers. Between 2003 and 2010, 128 AML patients in second complete remission were allografted following a preparative regimen of FB2 (n=88) or FB4 (n=40). The median time-to-neutrophil engraftment was similar whether patients received FB2 (16 (5-38) days) or FB4 (16 (9-29) days), p=0.45. A multivariate analysis showed that use of FB4 resulted in improved 2-year leukemia-free (HR=0.44 (95%CI=0.21, 0.94), p=0.03) and overall survival (HR=0.38 (95%CI=0.16, 0.86), p=0.02). Cumulative incidence of non-relapse mortality (2-year) for all patients was 21% (95%CI=14-28%). Our analysis suggests that FB4 improves 2-year leukemia-free and overall survival in AML allografted in second complete remission. A confirmatory randomized controlled trial that compares these two preparative regimens (FB2 vs. FB4) in AML in CR2 is definitely warranted. Copyright © 2015. Published by Elsevier Ltd.
    Leukemia Research 04/2015; 39(9). DOI:10.1016/j.leukres.2015.04.009 · 2.35 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Outcomes after unmanipulated haploidentical stem cell transplantation (Haplo) and after unrelated cord blood transplantation (UCBT) are encouraging and have become alternative options to treat patients with high risk acute leukemia without HLA matched donor. We compared outcomes after UCBT and Haplo in adults with de-novo acute myeloid leukemia(AML) and acute lymphoblastic leukemia (ALL). Median follow-up was 24 months. Analysis was performed separately for patients with AML, n=918 (Haplo=360, UCBT=558) and ALL, n=528 (Haplo=158 and UCBT=370). UCBT was associated with delayed engraftment and higher graft failure in both AML and ALL recipients. In multivariate analysis, UCBT was associated with lower incidence of chronic GVHD both in the AML group (HR=0.63, P=0.008) and in the ALL group(HR=0.58, P=0.01). Not statistically significant differences were observed between Haplo and UCBT for relapse incidence (HR=0.95, P=0.76 for AML and HR=0.82, P=0.31 for ALL), non-relapse mortality (HR=1.16, P=0.47 for AML and HR=1.23, P=0.23 for ALL) and leukemia-free survival (HR 0.78, P=0.78 for AML, and HR=1.00, P=0.84 for ALL). There were no statistically differences on main outcomes after unmanipulated Haplo and UCBT, and both approaches are valid for acute leukemia patients lacking a HLA matched donor. Both strategies expand the donor pool for patients in need.Leukemia accepted article preview online, 17 April 2015. doi:10.1038/leu.2015.98.
    Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 04/2015; 29(9). DOI:10.1038/leu.2015.98 · 10.43 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The guidelines for immunization of hematopoietic SCT (HSCT) recipients recommend three doses of antipneumococcal conjugate vaccine (PCV) from 3 to 6 months after transplant, followed by a dose of polysaccharide 23-valent (PPV23) vaccine at 12 months in the case of no GVHD or an additional PCV dose in the case of GVHD. Due to the lack of long-term data in the literature, there is no recommendation for boosts after 12 months. Our goal was to assess the maintenance of the immune response to pneumococcal vaccines in patients vaccinated 10 years ago according to current guidelines. Thirty surviving patients of the IDWP01 (Infectious Diseases Working Party 1) trial were assessed for antibody levels against the seven antigens of the PCV7 and against two of the PPV23-specific antigens. When compared with 24 months after transplant, the immune response did not significantly decrease but with important serotype-specific variability. There was no evidence that an additional dose of PPV23 given to 11/30 patients 2-11 years after transplant was beneficial. In long-term HSCT survivors with no or few GVHD vaccinated against Streptococcus pneumoniae according to the current guidelines, the specific immunity is not fully maintained a decade later. The optimal schedule of antipneumococcal vaccination in HSCT recipients after 12 months remains to be established.Bone Marrow Transplantation advance online publication, 13 April 2015; doi:10.1038/bmt.2015.42.
    Bone marrow transplantation 04/2015; 50(7). DOI:10.1038/bmt.2015.42 · 3.57 Impact Factor
  • Gastroenterology 04/2015; 148(4):S-163. DOI:10.1016/S0016-5085(15)30545-X · 16.72 Impact Factor
  • Leukemia Research 04/2015; 39:S68. DOI:10.1016/S0145-2126(15)30134-X · 2.35 Impact Factor

Publication Stats

6k Citations
1,630.60 Total Impact Points


  • 2011–2015
    • Polytech Paris-UPMC
      Lutetia Parisorum, Île-de-France, France
    • Thomas Jefferson University Hospitals
      Filadelfia, Pennsylvania, United States
  • 2007–2015
    • Pierre and Marie Curie University - Paris 6
      Lutetia Parisorum, Île-de-France, France
  • 2013–2014
    • Unité Inserm U1077
      Caen, Lower Normandy, France
  • 2010–2014
    • University of Paris-Est
      La Haye-Descartes, Centre, France
    • Assistance Publique – Hôpitaux de Paris
      Lutetia Parisorum, Île-de-France, France
    • Fred Hutchinson Cancer Research Center
      Seattle, Washington, United States
  • 2009
    • University of Freiburg
      Freiburg, Baden-Württemberg, Germany
  • 2002–2009
    • Sapienza University of Rome
      • Department of Cellular Biotechnology and Hematology BCE
      Roma, Latium, Italy
  • 2004
    • Karolinska Institutet
      • Department of Clinical Immunology
      Сольна, Stockholm, Sweden
  • 2003
    • Universität Ulm
      Ulm, Baden-Württemberg, Germany
    • University of Bologna
      Bolonia, Emilia-Romagna, Italy
  • 2001
    • University of Florence
      • Dipartimento di Chirurgia e Medicina Traslazionale (DCMT)
      Florens, Tuscany, Italy
  • 2000
    • University of Franche-Comté
      Becoinson, Franche-Comté, France
  • 1997
    • Institut des Systèmes Complexes, Paris Île-de-France
      Lutetia Parisorum, Île-de-France, France
    • Cliniques Universitaires Saint-Luc
      • Division of Hematology
      Bruxelles, Brussels Capital, Belgium
  • 1996–1997
    • Christian-Albrechts-Universität zu Kiel
      Kiel, Schleswig-Holstein, Germany